Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Παρόμοια τεκμήρια

• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  ανά: Pao, William, κ.ά.
  Έκδοση: (2005)
• Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
  ανά: Politi, Katerina, κ.ά.
  Έκδοση: (2010)
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  ανά: Pao, William, κ.ά.
  Έκδοση: (2004)
• Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
  ανά: Gong, Yixuan, κ.ά.
  Έκδοση: (2007)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  ανά: Zakowski, Maureen F., κ.ά.
  Έκδοση: (2009)